ANDA 210030, held by Hetero Labs Ltd V. Temozolomide.
As of Nov 16, 2026, ANDA 210030 (Temozolomide), held by Hetero Labs Ltd V, was first approved by FDA on Aug 23, 2024, with 0 approved supplements and 0 published complete response letters.
Temozolomide capsule is an alkylating drug indicated for the treatment of adults with:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 23, 2024 | Original application | Approved | None posted |
| Temozolomide5MG · capsule;oral | Temozolomide | Rx |
| Temozolomide20MG · capsule;oral | Temozolomide | Rx |
| Temozolomide100MG · capsule;oral | Temozolomide | Rx |
| Temozolomide140MG · capsule;oral | Temozolomide | Rx |
| Temozolomide180MG · capsule;oral | Temozolomide | Rx |
| Temozolomide250MG · capsule;oral | Temozolomide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters